“The anti-platelet derived growth factor (PDGF) combination agent Fovista (Ophthotech Corp.) showed statistically significant superior efficacy over ranibizumab (Lucentis, Genentech) monotherapy for the treatment of wet AMD, according to the results of a phase 2b study, which were recently reported in an Ophthotech release…”
Retinal Consultants of AZ is committed to clinical research and the pursuit of new and improved therapies for retinal diseases. Our Retinal Research Institute is proud to be intimately involved with this groundbreaking study. We helped to coordinate the study design, data collection, and were enthusiastically involved with study recruitment. In fact, we were the highest recruiters in the entire study. We would like to thank our referring doctors for helping to make this achievement possible. Without your help, we would not be able to contribute to this innovative clinical trial.
Read the rest of this article by EyeWireToday.com